fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine

Written by | 13 Jul 2022

People with hematologic malignancies—or blood cancers including leukemia, lymphoma, and multiple myeloma—have an impaired immune system due to their disease and its treatment, putting them at risk of… read more.

EU approves Oxbryta for hemolytic anemia due to sickle cell disease – Global Blood Therapeutics

Written by | 29 Jun 2022

Global Blood Therapeutics announced the European Commission (EC) has granted Marketing Authorization for Oxbryta (voxelotor) for the treatment of hemolytic anemia due to sickle cell disease (SCD) in… read more.

New research to help address blood shortages in Ireland

Written by | 26 Jun 2022

A study by RCSI University of Medicine and Health Sciences has identified barriers and motivators to blood donation for people from ethnic minority groups in Ireland. The findings… read more.

Immunity boosting treatment enhances CAR-T cell therapy for blood cancers

Written by | 15 Jun 2022

Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are… read more.

Prostate cancer linked to increased risk of venous thromboembolism

Written by | 1 Jun 2022

Researchers from Sweden have reported that, compared with men with no prostate cancer, men diagnosed with prostate cancer have a significantly higher risk of developing venous thromboembolism (VTE)… read more.

Major discovery provides new hope for blood cancer patients

Written by | 13 May 2022

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within… read more.

Early treatment with convalescent plasma significantly reduces the risk of COVID-related hospitalization

Written by | 30 Apr 2022

Researchers report that outpatients with recent SARS-CoV-2 infection treated with Covid-19 convalescent plasma within nine days of diagnosis have achieved a decreased the incidence of hospitalization when compared… read more.

Therapeutic target for aggressive blood cancer

Written by | 25 Apr 2022

A new study published today in the journal Genes & Development reveals a gene that normally suppresses the formation of tumours but is reprogrammed at the onset of acute promyelocytic… read more.

Researchers shorten manufacturing time for CAR T cell therapy

Written by | 1 Apr 2022

A new approach from Penn Medicine researchers could cut the time it takes to alter patients’ immune cells for infusion back into the body to find and attack… read more.

Clinicians report real-world results on the use of a new device to treat brain aneurysms

Written by | 19 Jan 2022

A recent international study led by researchers at Massachusetts General Hospital (MGH) and other institutions offers real-world results on the use of a novel device for treating brain… read more.

Could umbilical cord stem cells cure blood cancer?

Written by | 9 Jan 2022

Stem cells have promised to be the catalyst for major strides in medical research for decades. While progress in some fields has been slower than initially hoped, scientists… read more.

ChemoCentryx announces approval in Japan of Tavneos for the treatment of ANCA-associated vasculitis

Written by | 26 Dec 2021

ChemoCentryx, Inc., announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market Tavneos™ (avacopan), an orally administered… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.